US$ 20.49
sglt2 inhibitors and glp-1 receptor agonists Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Perioperative GLP-1/GIP & SGLT2 Inhibitors
Description
References 1 American Diabetes Association Professional Practice Committee
Analysis of six studies indicated a significantly higher incidence of nausea in GLP-1RAs group compared to the placebo group, with an odds ratio (OR) of 2.01 (95% CI 1.24 to 3.27) (Fig

Just three years later, in 2022, the game shifted again with tirzepatide (Mounjaro)

Lau J, Bloch P, Schffer L, Pettersson I, Spetzler J, Kofoed J, et al

Kosowska A, Gallego-Colon E, Garczorz W, Klych-Ratuszny A, Aghdam MR, Woz Niak M, et al
